Bank of America Reiterates “Buy” Rating for UnitedHealth Group (UNH)

Bank of America reiterated their buy rating on shares of UnitedHealth Group (NYSE:UNH) in a report released on Wednesday, April 17th, Stock Target Advisor reports. They currently have a $290.00 price objective on the healthcare conglomerate’s stock, down from their previous price objective of $320.00.

A number of other research firms have also weighed in on UNH. ValuEngine lowered UnitedHealth Group from a buy rating to a hold rating in a research note on Wednesday, February 27th. Credit Suisse Group reiterated a buy rating and issued a $310.00 target price on shares of UnitedHealth Group in a research report on Friday, February 8th. Oppenheimer boosted their target price on UnitedHealth Group from $300.00 to $305.00 and gave the stock an outperform rating in a research report on Wednesday, January 16th. Zacks Investment Research downgraded UnitedHealth Group from a buy rating to a hold rating in a research report on Tuesday, March 19th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $310.00 target price on shares of UnitedHealth Group in a research report on Tuesday, January 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $290.47.

Shares of UNH stock traded up $2.62 during mid-day trading on Wednesday, hitting $240.59. The company’s stock had a trading volume of 4,373,591 shares, compared to its average volume of 8,753,273. UnitedHealth Group has a 52-week low of $208.07 and a 52-week high of $287.94. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.73 and a quick ratio of 0.73. The stock has a market capitalization of $226.15 billion, a P/E ratio of 18.68, a P/E/G ratio of 1.27 and a beta of 0.74.

UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings results on Tuesday, April 16th. The healthcare conglomerate reported $3.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.60 by $0.13. UnitedHealth Group had a return on equity of 25.07% and a net margin of 5.45%. The firm had revenue of $60.30 billion during the quarter, compared to analysts’ expectations of $59.72 billion. During the same quarter in the previous year, the business earned $3.04 earnings per share. The company’s revenue was up 9.2% on a year-over-year basis. As a group, analysts anticipate that UnitedHealth Group will post 14.7 earnings per share for the current year.

In other UnitedHealth Group news, CEO David S. Wichmann purchased 20,000 shares of UnitedHealth Group stock in a transaction dated Friday, May 3rd. The shares were purchased at an average cost of $231.79 per share, for a total transaction of $4,635,800.00. Following the completion of the acquisition, the chief executive officer now owns 904,367 shares in the company, valued at approximately $209,623,226.93. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gail R. Wilensky sold 2,930 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $253.39, for a total value of $742,432.70. Following the completion of the sale, the director now owns 64,726 shares in the company, valued at $16,400,921.14. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,930 shares of company stock worth $6,746,683. Company insiders own 0.87% of the company’s stock.

A number of large investors have recently made changes to their positions in UNH. CI Investments Inc. boosted its position in UnitedHealth Group by 5.8% during the 3rd quarter. CI Investments Inc. now owns 949,719 shares of the healthcare conglomerate’s stock valued at $252,663,000 after acquiring an additional 52,023 shares in the last quarter. Martingale Asset Management L P boosted its position in UnitedHealth Group by 1.7% during the 3rd quarter. Martingale Asset Management L P now owns 214,133 shares of the healthcare conglomerate’s stock valued at $56,969,000 after acquiring an additional 3,598 shares in the last quarter. Blue Fin Capital Inc. boosted its position in UnitedHealth Group by 7.2% during the 3rd quarter. Blue Fin Capital Inc. now owns 10,689 shares of the healthcare conglomerate’s stock valued at $2,844,000 after acquiring an additional 722 shares in the last quarter. Capital Guardian Trust Co. boosted its position in UnitedHealth Group by 0.6% during the 3rd quarter. Capital Guardian Trust Co. now owns 276,790 shares of the healthcare conglomerate’s stock valued at $73,637,000 after acquiring an additional 1,571 shares in the last quarter. Finally, Bamco Inc. NY boosted its position in UnitedHealth Group by 230.0% during the 3rd quarter. Bamco Inc. NY now owns 2,419 shares of the healthcare conglomerate’s stock valued at $644,000 after acquiring an additional 1,686 shares in the last quarter. 87.49% of the stock is currently owned by institutional investors.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Read More: What is a Tariff?

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.